Cargando…

Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review

With a globally estimated 58 million people affected by, chronic hepatitis C virus (HCV) infection still represents a hard challenge for scientific community. A chronic course can occur among patients with a weak innate ad adaptive response with cirrhosis and malignancies as main consequences. Oncol...

Descripción completa

Detalles Bibliográficos
Autor principal:	Spera, Anna Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055195/ https://www.ncbi.nlm.nih.gov/pubmed/35582286 http://dx.doi.org/10.4254/wjh.v14.i3.525

Ejemplares similares

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
por: Muzica, Cristina Maria, et al.
Publicado: (2020)

Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals
por: Cerrito, Lucia, et al.
Publicado: (2021)

Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review
por: Spera, Anna Maria
Publicado: (2021)

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022)

Era of direct acting anti-viral agents for the treatment of hepatitis C
por: Ahmed, Monjur
Publicado: (2018)

Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?
por: Butt, Amna Subhan, et al.
Publicado: (2018)

Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis
por: Wu, Ya-Li, et al.
Publicado: (2019)

Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment
por: Spera, Anna Maria
Publicado: (2022)

Fibrosis regression following hepatitis C antiviral therapy
por: Elsharkawy, Aisha, et al.
Publicado: (2022)

Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease
por: Khoo, Tiffany, et al.
Publicado: (2021)

Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched
por: Compagnoni, Stella, et al.
Publicado: (2021)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
por: Baumert, Thomas F., et al.
Publicado: (2017)

Discontinuation of antiviral therapy in chronic hepatitis B patients
por: Medas, Renato, et al.
Publicado: (2021)

Challenges in the discontinuation of chronic hepatitis B antiviral agents
por: Kaewdech, Apichat, et al.
Publicado: (2021)

Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings
por: Said, Zeinab Nabil Ahmed, et al.
Publicado: (2022)

Influence of the COVID-19 pandemic in the gastrointestinal oncology setting: An overview
por: de Brito, Breno Bittencourt, et al.
Publicado: (2022)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches
por: Cakir, Merve, et al.
Publicado: (2021)

Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C
por: Abdulla, Maheeba, et al.
Publicado: (2022)

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting
por: Chen, Jian-Hong, et al.
Publicado: (2017)

Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations
por: Omran, Dalia, et al.
Publicado: (2018)

Clinical characteristics and outcomes of patients with hepatic angiomyolipoma: A literature review
por: Calame, Paul, et al.
Publicado: (2021)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Autoimmune hepatitis in genetic syndromes: A literature review
por: Capra, Anna Paola, et al.
Publicado: (2021)

The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia
por: Alarfaj, Sumaiah J., et al.
Publicado: (2022)

Clinical infections in neurosurgical oncology: An overview
por: Velnar, Tomaz, et al.
Publicado: (2023)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis
por: Alian, Samah M., et al.
Publicado: (2020)

Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
por: Iliescu, Elena Laura, et al.
Publicado: (2020)

Safety and efficacy of directly‐acting antiviral therapy for chronic hepatitis C virus in elderly people
por: De Santis, Adriano, et al.
Publicado: (2021)

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
por: Ryu, Ji Eun, et al.
Publicado: (2022)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Effectiveness and safety of COVID-19 vaccines in patients with oncological diseases: State-of-the-art
por: Ivanov, Nedelcho, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sc8otmp20fdfb0lnoa5o6jlcmk